Organization | National Malaria Control Programme, The Gambia

National Malaria Control Programme, The Gambia Report issue

Government Phase 3

Founded: Gambia (1980)

Organization Overview

First Clinical Trial

2003

NCT00118807

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2018

Timeline

NOW

Now

Alternative names

National Malaria Control Programme, The Gambia

Active Ingredients

Drugs in Phase 3 Trials (12)

amodiaquine (camoquin) (1 trial)

artesunate (1 trial)

chloroquine (1 trial)

chlorproguanil (1 trial)

coartem (1 trial)

dapsone (aczone) (1 trial)

dihydroartemisinin (1 trial)

ivermectin (stromectol) (1 trial)

lumefantrine (Coartem) (1 trial)

piperaquine (1 trial)

pyrimethamine (daraprim) (1 trial)

sulfadoxine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Malaria (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 3
# of Trial APIs: 12